This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.
Pathologically confirmed HER2-positive
Mandatory provision of tumor tissue sample
Patients who have at least one measurable lesion
Mandatory provision of tumor tissue sample
Uncontrolled central nervous system (CNS) metastases
Spinal cord compression
Carcinomatous meningitis
Acute coronary syndromes
Yuhan Corporation
Lead sponsor